Suppr超能文献

光遗传学在视觉修复中的应用:从原理验证到转化挑战。

Optogenetics for visual restoration: From proof of principle to translational challenges.

机构信息

The Nuffield Laboratory of Ophthalmology, Jules Thorn SCNi, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, OX1 3QU, United Kingdom; Institute of Physiology and Pathophysiology, Department of Neurophysiology, Philipps University, 35037, Marburg, Germany.

The Nuffield Laboratory of Ophthalmology, Jules Thorn SCNi, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, OX1 3QU, United Kingdom; The Institute of Ophthalmology, University College London, EC1V 9EL, United Kingdom; Moorfields Eye Hospital, London, EC1V 2PD, United Kingdom.

出版信息

Prog Retin Eye Res. 2022 Nov;91:101089. doi: 10.1016/j.preteyeres.2022.101089. Epub 2022 Jun 9.

Abstract

Degenerative retinal disorders are a diverse family of diseases commonly leading to irreversible photoreceptor death, while leaving the inner retina relatively intact. Over recent years, innovative gene replacement therapies aiming to halt the progression of certain inherited retinal disorders have made their way into clinics. By rendering surviving retinal neurons light sensitive optogenetic gene therapy now offers a feasible treatment option that can restore lost vision, even in late disease stages and widely independent of the underlying cause of degeneration. Since proof-of-concept almost fifteen years ago, this field has rapidly evolved and a detailed first report on a treated patient has recently been published. In this article, we provide a review of optogenetic approaches for vision restoration. We discuss the currently available optogenetic tools and their relative advantages and disadvantages. Possible cellular targets will be discussed and we will address the question how retinal remodelling may affect the choice of the target and to what extent it may limit the outcomes of optogenetic vision restoration. Finally, we will analyse the evidence for and against optogenetic tool mediated toxicity and will discuss the challenges associated with clinical translation of this promising therapeutic concept.

摘要

退行性视网膜疾病是一组多样化的疾病,通常导致不可逆转的光感受器死亡,而内视网膜相对完整。近年来,旨在阻止某些遗传性视网膜疾病进展的创新基因替代疗法已进入临床。通过使存活的视网膜神经元对光敏感,光遗传学基因疗法现在提供了一种可行的治疗选择,可以恢复丧失的视力,即使在疾病晚期,并且广泛独立于退行性疾病的根本原因。自近十五年前的概念验证以来,该领域发展迅速,最近发表了一篇关于治疗患者的详细第一份报告。在本文中,我们回顾了用于视力恢复的光遗传学方法。我们讨论了目前可用的光遗传学工具及其相对优缺点。将讨论可能的细胞靶标,并将解决视网膜重塑如何影响靶标的选择以及在多大程度上可能限制光遗传学视力恢复的结果的问题。最后,我们将分析光遗传学工具介导的毒性的证据,并讨论与这一有前途的治疗概念的临床转化相关的挑战。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验